A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
New England Journal of Medicine2020Vol. 382(19), pp. 1787–1799
Citations Over TimeTop 1% of 2020 papers
Bin Cao, Yeming Wang, Danning Wen, Wen Liu, Jingli Wang, Guohui Fan, Lianguo Ruan, Bin Song, Yanping Cai, Ming Wei, Xingwang Li, Jiaan Xia, Nanshan Chen, Jie Xiang, Ting Yu, Tao Bai, Xuelei Xie, Li Zhang, Caihong Li, Ye Yuan, Hua Chen, Huadong Li, Han-Ping Huang, Shengjing Tu, Fengyun Gong, Ying Liu, Yuan Wei, Chongya Dong, Fei Zhou, Xiaoying Gu, Jiuyang Xu, Zhibo Liu, Yi Zhang, Hui Li, Lianhan Shang, Ke Wang, Kunxia Li, Xia Zhou, Xuan Dong, Zhaohui Qu, Sixia Lu, Xujuan Hu, Shunan Ruan, Shanshan Luo, Jing Wu, Peng Lü, Fang Cheng, Li-hong Pan, Jun Zou, Chunmin Jia, Juan Wang, Xia Liu, Shuzhen Wang, Xudong Wu, Ge Qin, Jing He, Haiyan Zhan, Fang Qiu, Li Guo, Chaolin Huang, Thomas Jaki, Frederick G. Hayden, Peter Horby, Dingyu Zhang, Chen Wang
Abstract
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
Related Papers
- → Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019(2020)39 cited
- → Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir(2009)27 cited
- → Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice‐Daily to Once‐Daily Therapy(2007)17 cited
- PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.(2015)
- → Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir(2012)3 cited